Drug Trial Radar · NCT05972174
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,504
Actual
Start
Jul 10, 2023
Primary completion
Jul 16, 2024
Study completion Jul 16, 2024
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).
Conditions
- Influenza
Interventions
mRNA-1018 for H5N8Biological
Sterile liquid for injection
mRNA-1018 for H7N9Biological
Sterile liquid for injection
mRNA-1018 for H5 OnlyBiological
Sterile liquid for injection
mRNA-1018 for H7 OnlyBiological
Sterile liquid for injection
mRNA-1018 for H5 Only-CGBiological
Sterile liquid for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 29 (7 days after each injection)
- Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 43 (21 days after each injection)
- Number of Participants with AEs Leading to Discontinuation From StudyTime frame: Day 1 to Day 205 (end of study [EoS])
- Number of Participants with Medically-Attended AEs (MAAEs)Time frame: Day 1 to Day 205 (EoS)
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Day 1 to Day 205 (EoS)
- Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: Day 1 to Day 205 (EoS)
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
CenExel RCA
Hollywood, Florida
Velocity Clinical Research
Savannah, Georgia
Johnson County Clin-Trials
Lenexa, Kansas
DM Clinical Research
Southfield, Michigan
Velocity Clinical Research
Lincoln, Nebraska
Velocity Clinical Research Providence
East Greenwich, Rhode Island
DM Clinical Research
Sugar Land, Texas
DM Clinical Research
Tomball, Texas
J. Lewis Research, Inc/Jordan River Family Medicine
South Jordan, Utah
Western Hospital Edinburgh
Edinburgh, United Kingdom
Royal Free Hospital
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
London, United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
St Georges Vaccine Institute Cranmer Terrace
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Velocity Clinical Research
North Finchley, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, England, United Kingdom
Southampton General Hospital
Southampton, England, United Kingdom
University Hospitals Birmingham
Birmingham, London, United Kingdom
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, London, United Kingdom
University Hospitals
Bristol, London, United Kingdom
Cardiff and Vale University
Cardiff, London, United Kingdom
Northern Care Alliance
Salford, London, United Kingdom
Royal Cornwall Hospital
Truro, London, United Kingdom
North Wales Clinical Research Centre
Wrexham, London, United Kingdom
Quadram Institute NNUH CRF
Norwich, Norfolk, United Kingdom
Lakeside Healthcare Research Unit
Corby, Northamptonshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.